Allergan (FRA:AG4) Shiller PE Ratio : 138.61 (As of Jun. 21, 2024)

View and export this data going back to . Start your Free Trial

What is Allergan Shiller PE Ratio?

As of today (2024-06-21), Allergan's current share price is €225.94. Allergan's E10 for the quarter that ended in Dec. 2014 was €1.63. Allergan's Shiller PE Ratio for today is 138.61.

The historical rank and industry rank for Allergan's Shiller PE Ratio or its related term are showing as below:

FRA:AG4's Shiller PE Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 24.07
* Ranked among companies with meaningful Shiller PE Ratio only.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Allergan's adjusted earnings per share data for the three months ended in Dec. 2014 was €1.427. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €1.63 for the trailing ten years ended in Dec. 2014.

Shiller PE for Stocks: The True Measure of Stock Valuation

Allergan Shiller PE Ratio Historical Data

The historical data trend for Allergan's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergan Shiller PE Ratio Chart

Allergan Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Shiller PE Ratio

Get a 7-Day Free Trial

71.51

78.70

63.11

58.58

107.90

Allergan Quarterly Data
	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14
Shiller PE Ratio	Get a 7-Day Free Trial															58.58	62.32	84.60	91.90	107.90

Competitive Comparison of Allergan's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Allergan's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergan's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergan's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Allergan's Shiller PE Ratio falls into.

Allergan Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Allergan's Shiller PE Ratio for today is calculated as

Shiller PE Ratio	=	Share Price	/	E10
	=	225.94	/	1.63
	=	138.61

Allergan's E10 for the quarter that ended in Dec. 2014 is calculated as:

For example, Allergan's adjusted earnings per share data for the three months ended in Dec. 2014 was:

Adj_EPS	=	Earnings per Share (Diluted)	/	CPI of Dec. 2014 (Change)	*	Current CPI (Dec. 2014)
	=	1.427	/	99.0697	*	99.0697
	=	1.427

Current CPI (Dec. 2014) = 99.0697.

Allergan Quarterly Data

	Earnings per Share (Diluted)	CPI	Adj_EPS
200503	0.227	81.555	0.276
200506	0.103	82.062	0.124
200509	0.458	83.876	0.541
200512	0.431	83.032	0.514
200603	-1.367	84.298	-1.607
200606	0.190	85.606	0.220
200609	0.275	85.606	0.318
200612	0.329	85.142	0.383
200703	0.106	86.640	0.121
200706	0.335	87.906	0.378
200709	0.367	87.964	0.413
200712	0.357	88.616	0.399
200803	0.225	90.090	0.247
200806	0.302	92.320	0.324
200809	0.383	92.307	0.411
200812	0.329	88.697	0.367
200903	0.115	89.744	0.127
200906	0.414	91.003	0.451
200909	0.398	91.120	0.433
200912	0.495	91.111	0.538
201003	0.405	91.821	0.437
201006	0.638	91.962	0.687
201009	-1.686	92.162	-1.812
201012	0.617	92.474	0.661
201103	0.364	94.283	0.382
201106	0.548	95.235	0.570
201109	0.589	95.727	0.610
201112	0.686	95.213	0.714
201203	0.560	96.783	0.573
201206	0.765	96.819	0.783
201209	0.636	97.633	0.645
201212	0.809	96.871	0.827
201303	0.031	98.209	0.031
201306	0.902	98.518	0.907
201309	0.748	98.790	0.750
201312	0.758	98.326	0.764
201403	0.615	99.695	0.611
201406	1.008	100.560	0.993
201409	0.799	100.428	0.788
201412	1.427	99.070	1.427

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Allergan (FRA:AG4) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.

Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.

Allergan Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Allergan's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergan (FRA:AG4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergan Inc (FRA:AG4) » Definitions » Shiller PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Allergan IncÂ incorporated in Delaware in 1977.Â It is a multi-specialty health care company. The Company is engaged in the developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products that enable people to live life to its full potential - to see more clearly, move more freely and express themselves more fully. It offers products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets in more than 100 countries around the world. It is also engaged in specialty pharmaceutical, biologic and medical device research and development. The Company's business segments are specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease;Â BotoxÂ for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologics products. The medical devices segment produces medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; and facial aesthetics products. The Company sells its products directly through itsÂ own sales subsidiaries in approximately 40 countries and, supplemented by independent distributors, in over 100 countries.Â Its products are sold to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies and medical practitioners. The Company also utilize distributors for its products in smaller international markets.Â The Company's competitors include Akorn, Inc., Alcon Laboratories, Inc./Novartis AG, Abbott Laboratories, Alimera Sciences, Inc., BauschÂ & Lomb, Inc., a division of Valeant, Genentech/Hoffmann La Roche AG, MerckÂ & Co., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Santen Seiyaku. Mentor and Sientra, Inc., or Sientra, a partner of Silimed, LifeCell Corporation, CR Bard Inc. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations, including the U.S. Occupational Safety and Health Act, the U.S. Toxic Substances Control Act, the U.S. Resource Conservation and Recovery Act, Superfund Amendments and Reauthorization Act, Comprehensive Environmental Response, Compensation and Liability Act and other current and potential future federal, state or local regulations.

Allergan (FRA:AG4) Headlines

No Headlines